$6.59
4.69% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US04335A1051
Symbol
ARVN

Arvinas, Inc. Stock price

$6.59
-1.21 15.47% 1M
-11.10 62.75% 6M
-12.59 65.65% YTD
-17.98 73.19% 1Y
-47.96 87.93% 3Y
-21.36 76.43% 5Y
-9.47 58.97% 10Y
-9.47 58.97% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.30 4.69%
ISIN
US04335A1051
Symbol
ARVN
Industry

Key metrics

Basic
Market capitalization
$483.5m
Enterprise Value
$-377.3m
Net debt
positive
Cash
$861.2m
Shares outstanding
73.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.3 | 1.7
EV/Sales
negative | negative
EV/FCF
0.9
P/B
0.8
Financial Health
Equity Ratio
51.5%
Return on Equity
-35.4%
ROCE
-15.8%
ROIC
159.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$372.8m | $283.4m
EBITDA
$-111.7m | $-117.9m
EBIT
$-118.6m | $-173.7m
Net Income
$-72.6m | $-111.7m
Free Cash Flow
$-399.0m
Growth (TTM | estimate)
Revenue
73.5% | 7.6%
EBITDA
81.5% | 51.6%
EBIT
80.5% | 30.6%
Net Income
86.5% | 43.8%
Free Cash Flow
-83.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-30.0% | -41.6%
EBIT
-31.8%
Net
-19.5% | -39.4%
Free Cash Flow
-107.0%
More
EPS
$-1.0
FCF per Share
$-5.5
Short interest
10.9%
Employees
430
Rev per Employee
$610.0k
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Arvinas, Inc. forecast:

17x Buy
63%
10x Hold
37%

Analyst Opinions

27 Analysts have issued a Arvinas, Inc. forecast:

Buy
63%
Hold
37%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
373 373
73% 73%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 162 162
9% 9%
43%
- Research and Development Expense 330 330
49% 49%
88%
-112 -112
81% 81%
-30%
- Depreciation and Amortization 6.90 6.90
44% 44%
2%
EBIT (Operating Income) EBIT -119 -119
80% 80%
-32%
Net Profit -73 -73
86% 86%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –
Neutral
Seeking Alpha
6 days ago
Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.
Neutral
GlobeNewsWire
6 days ago
– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer –
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 430
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today